^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    13h
    A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov)
    P3, N=38769, Completed, Seqirus | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Nov 2026 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date
    14h
    rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Sichuan Huiyang Life Science and Technology Corporation
    New P2 trial
    16h
    Immunity and Safety of Covid-19 Synthetic Minigene Vaccine (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Jul 2023 --> Dec 2029
    Trial completion date • Trial primary completion date
    16h
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, National Cancer Institute (NCI) | N=16 --> 26
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    18h
    A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults (clinicaltrials.gov)
    P1, N=196, Not yet recruiting, GlaxoSmithKline
    New P1 trial
    18h
    Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial. (PubMed, Nat Commun)
    In this single-arm, phase I study (NCT04117087), we evaluated mKRAS-VAX, a pooled mutant KRAS (mKRAS) peptide vaccine targeting six KRAS mutations with nivolumab and ipilimumab in 13 patients with pretreated metastatic MMRp/MSS CRC. mKRAS-VAX elicited an increase in tumor-specific mKRAS-reactive T-cells in 8/12 biomarker-evaluable patients (75%) by direct ex vivo IFNγ ELISpot and in 12 patients (100%) following in vitro expansion. Our findings support further development of mKRAS vaccines with ICIs for advanced MMRp/MSS CRC.
    P1 data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • IFNG (Interferon, gamma)
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • KRAS peptide vaccine
    20h
    Safety and Immunity of Covid-19 aAPC Vaccine (clinicaltrials.gov)
    P1, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Jul 2023 --> Dec 2029
    Trial completion date • Trial primary completion date
    23h
    RSV Immunisation Status in Queensland (Australia) (clinicaltrials.gov)
    P=N/A, N=1200, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents (clinicaltrials.gov)
    P3, N=1200, Recruiting, Pfizer
    New P3 trial
    1d
    A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (clinicaltrials.gov)
    P1, N=50, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
    Trial completion
    1d
    EVM16CX01: EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors (clinicaltrials.gov)
    P1, N=78, Recruiting, Peking University | Trial completion date: Jun 2028 --> Dec 2028
    Trial completion date
    |
    Tevimbra (tislelizumab-jsgr)
    1d
    A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov)
    P1/2, N=551, Completed, GlaxoSmithKline | Phase classification: P1 --> P1/2
    Phase classification